Teva launches Oxcarbazepine
Teva Pharma announce the introduction and availability of Oxcarbazepine Tablets. This product is AB rated and bioequivalent to Trileptal®* Tablets. Oxcarbazepine Tablets are available in 150 mg, 300 mg, and 600 mg strengths, in bottle sizes of 100.“Generic pharmaceuticals are playing an increasingly important role in healthcare costcontainment,” states John Denman, V.P. Sales and Marketing.“Teva Pharmaceuticals continues tolead the way with timely new product launches.”Teva Pharmaceuticals, located in North Wales, Pennsylvania, is the leading pharmaceutical manufacturer for both new and total prescriptions.‡ The company has an aggressive Research andDevelopment effort and one of the best overall ANDA approval records in the industry
Ahead of the Bell: Pharmaceutical Suits
The pharmaceutical industry will be watching the Supreme Court Monday to see if the justices will give drug makers similar protection from lawsuits recently handed to medical-device makers.
The court ruled Wednesday in a case involving Medtronic Inc. that federal regulation of advanced medical devices preempts lawsuits in state courts against their manufacturers. Please read the complete article on following link
http://www.chron.com/disp/story.mpl/ap/fn/5567036.html
Abbott receives FDA approval for juvenile idiopathic arthritis drug
Abbott Friday said it had received marketing approval from the USFDA for its Humira drug, which treats juvenile idiopathic arthritis. The approval was based on the safety and efficacy results from a clinical trial, Abbott said.
Genetech wins U.S. approval to use Avastin to treat breast cancer
Genentech won U.S. approval to market its top-selling treatment Avastin for women with breast cancer, giving the company a chance to add more than $700 million in sales this year.
Avastin was cleared for marketing by the U.S. Food and Drug Administration, combined with paclitaxel chemotherapy, for women whose breast cancer had spread, the company said in a statement. Avastin, the first product to work by cutting off blood supply to tumors, was already approved for colorectal and lung malignancies.The FDA overruled one of its advisory panels, which recommended 5-4 in December against approving the medicine for breast cancer. The committee said Avastin's benefit of slowing the spread of tumors was not worth the risk of serious side effects, including high blood pressure and death. Avastin generated $2.3 billion in U.S. sales in 2007.
Teva Pharma announce the introduction and availability of Oxcarbazepine Tablets. This product is AB rated and bioequivalent to Trileptal®* Tablets. Oxcarbazepine Tablets are available in 150 mg, 300 mg, and 600 mg strengths, in bottle sizes of 100.“Generic pharmaceuticals are playing an increasingly important role in healthcare costcontainment,” states John Denman, V.P. Sales and Marketing.“Teva Pharmaceuticals continues tolead the way with timely new product launches.”Teva Pharmaceuticals, located in North Wales, Pennsylvania, is the leading pharmaceutical manufacturer for both new and total prescriptions.‡ The company has an aggressive Research andDevelopment effort and one of the best overall ANDA approval records in the industry
Ahead of the Bell: Pharmaceutical Suits
The pharmaceutical industry will be watching the Supreme Court Monday to see if the justices will give drug makers similar protection from lawsuits recently handed to medical-device makers.
The court ruled Wednesday in a case involving Medtronic Inc. that federal regulation of advanced medical devices preempts lawsuits in state courts against their manufacturers. Please read the complete article on following link
http://www.chron.com/disp/story.mpl/ap/fn/5567036.html
Abbott receives FDA approval for juvenile idiopathic arthritis drug
Abbott Friday said it had received marketing approval from the USFDA for its Humira drug, which treats juvenile idiopathic arthritis. The approval was based on the safety and efficacy results from a clinical trial, Abbott said.
Genetech wins U.S. approval to use Avastin to treat breast cancer
Genentech won U.S. approval to market its top-selling treatment Avastin for women with breast cancer, giving the company a chance to add more than $700 million in sales this year.
Avastin was cleared for marketing by the U.S. Food and Drug Administration, combined with paclitaxel chemotherapy, for women whose breast cancer had spread, the company said in a statement. Avastin, the first product to work by cutting off blood supply to tumors, was already approved for colorectal and lung malignancies.The FDA overruled one of its advisory panels, which recommended 5-4 in December against approving the medicine for breast cancer. The committee said Avastin's benefit of slowing the spread of tumors was not worth the risk of serious side effects, including high blood pressure and death. Avastin generated $2.3 billion in U.S. sales in 2007.
